Early Asset Commercialisation in Biotech & Pharma – why not?
- Published on
- Aug 2017
Despite the fact appointing commercial leaders early in the research and development process has the potential to benefit biotech and pharma companies that are looking to launch, a large number of companies still don’t do it. We spoke with Max Eldridge, a Senior Recruitment Consultant at Real, to find out more about the benefits of appointing commercial leaders early on in order to overcome challenges that these organisations are facing.